Videos

Long-Term Strategies in Advanced HCC

Later Line Therapeutic Decisions in Metastatic HCC

Later Line Therapeutic Decisions in Metastatic HCC

Jessica Islam, MPH, a PhD student at the University of North Carolina at Chapel Hill Gillings School of Global Public Health, discusses research that projected cancer incidence in the HIV-positive population in the United States through 2030.

Hideho Okada, MD, PhD, director, Brain Tumor Immunotherapy Center, professor of Neurological Surgery, University of California, San Francisco, discusses a study exploring vaccination in low-grade glioma aiming at prevention of high-grade transformation.

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses why CheckMate-026 was not successful in showing an improvement in progression-free survival (PFS) for patients with advanced non-small cell lung cancer.

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses treating patients with non-small cell lung cancer (NSCLC) who do not have an actionable oncogenic driver.

Ruth O’Regan, MD, discusses results of BELLE-3, a phase III study of buparlisib (BKM120) plus fulvestrant (Faslodex) in postmenopausal women with hormone receptor (HR)-positive, HER2-negative breast cancer.

Treatment of Malignant Melanoma

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses indoximod as an active IDO inhibitor in advanced melanoma.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the role of nab-paclitaxel (Abraxane) in the treatment of triple-negative breast cancer (TNBC). 

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.